Statutory Profit Doesn't Reflect How Good Green Cross Medical Science's (KOSDAQ:142280) Earnings Are

Even though Green Cross Medical Science Corporation's (KOSDAQ:142280) recent earnings release was robust, the market didn't seem to notice. Our analysis suggests that investors might be missing some promising details.

The Impact Of Unusual Items On Profit

Importantly, our data indicates that Green Cross Medical Science's profit was reduced by ₩1.4b, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Green Cross Medical Science took a rather significant hit from unusual items in the year to December 2024. All else being equal, this would likely have the effect of making the statutory profit look worse than its underlying earnings power.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Green Cross Medical Science.

Our Take On Green Cross Medical Science's Profit Performance

As we discussed above, we think the significant unusual expense will make Green Cross Medical Science's statutory profit lower than it would otherwise have been. Because of this, we think Green Cross Medical Science's underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! Furthermore, it has done a great job growing EPS over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. You'd be interested to know, that we found 2 warning signs for Green Cross Medical Science and you'll want to know about these.

This note has only looked at a single factor that sheds light on the nature of Green Cross Medical Science's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.